{"id":"W2427633307","doi":"10.1038/ajg.2016.236","title":"The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium","year":2016,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":323,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"U.S. National Library of Medicine; National Human Genome Research Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research; Crohn's and Colitis Foundation","keywords":"Medicine; Hazard ratio; Vedolizumab; Internal medicine; Discontinuation; Adverse effect; Gastroenterology; Retrospective cohort study; Surgery; Confidence interval; Proportional hazards model; Inflammatory bowel disease; Disease","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008567645,0.0002719788,0.0004329801,0.0005377121,0.0002421721,0.0007795469,0.0003940516,0.0004267559,0.0007785051],"category_scores_gemma":[0.01250422,0.0001411431,0.0008494973,0.0008211014,0.0004215428,0.0004482154,0.0008158521,0.0003304799,0.0001167562],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006751643,"about_ca_system_score_gemma":0.001118986,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004595331,"about_ca_topic_score_gemma":0.005180084,"domain_scores_codex":[0.994325,0.003426392,0.0004888501,0.0004680394,0.001090693,0.0002010201],"domain_scores_gemma":[0.9850597,0.005054647,0.006532684,0.001067981,0.001352613,0.0009323302],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01209403,0.00031879,0.9559115,0.0002409297,0.00186111,0.00007374217,0.0001689684,0.0005641973,0.0004121603,0.0001096355,0.001315925,0.02692906],"study_design_scores_gemma":[0.001340172,0.002564209,0.9917513,0.0001072764,0.0007615315,0.0002624952,0.0001617153,0.000592789,0.0002821762,0.00003825952,0.002115529,0.00002259237],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933572,0.003292977,0.0001849979,0.0003470659,0.00001358636,0.00007697385,0.001966506,0.00000902397,0.0007515671],"genre_scores_gemma":[0.9966954,0.0007673849,0.0001910069,0.000128195,0.00003526008,0.0000356715,0.002049414,0.00000396268,0.00009379467],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008567645,"threshold_uncertainty_score":0.04531056,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005735074284652051,"score_gpt":0.2386958072047946,"score_spread":0.2329607329201426,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}